The association of nutritional and inflammatory biomarkers with overall survival in patients with non‐small‐cell lung cancer treated with immune checkpoint inhibitors
| Title: | The association of nutritional and inflammatory biomarkers with overall survival in patients with non‐small‐cell lung cancer treated with immune checkpoint inhibitors |
|---|---|
| Authors: | I. M. Horstman, P. C. Vinke, E. Suazo‐Zepeda, T. J. N. Hiltermann, M. A. Heuvelmans, E. Corpeleijn, G. H. deBock |
| Source: | Thoracic Cancer, Vol 15, Iss 23, Pp 1764-1771 (2024) |
| Publisher Information: | Wiley, 2024. |
| Publication Year: | 2024 |
| Collection: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| Subject Terms: | non‐small‐cell lung cancer, immunotherapy, immune checkpoint inhibitors, nutritional and inflammatory biomarkers, prognostic markers, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| More Details: | Abstract Objectives Pretreatment biomarkers are needed to identify patients with non‐small‐cell lung cancer (NSCLC) likely to have worse survival. This ensures that only patients with a real chance of benefit receive immune checkpoint inhibitor (ICI) treatment. In this study, we examined the associations of baseline nutritional and inflammatory biomarkers with overall survival in a real‐world cohort of NSCLC patients who received ICIs. Materials and Methods We used prospectively collected data from the OncoLifeS data biobank. The cohort included 500 advanced‐stage NSCLC patients treated with ICIs from May 2015 to June 2021. Biomarkers were evaluated within 2 weeks before ICI treatment: neutrophil‐to‐lymphocyte ratio, C‐reactive protein (CRP), Glasgow prognostic score, CRP/albumin ratio (CAR), prognostic nutritional index (PNI), and advanced lung cancer inflammation index. For each biomarker, low‐ and high‐risk groups were defined using literature‐based cut‐offs. Adjusted hazard ratios (aHRs) and 95% confidence intervals (95% CIs) were estimated using adjusted survival analysis. Results Most patients were male (60.8%), the mean baseline age was 65 ± 9 years, and 88% had stage IV disease. For each biomarker, low‐risk patients had better overall survival (all, p |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 1759-7714 1759-7706 |
| Relation: | https://doaj.org/toc/1759-7706; https://doaj.org/toc/1759-7714 |
| DOI: | 10.1111/1759-7714.15401 |
| Access URL: | https://doaj.org/article/dbf5d2f74ba34f8f8e2c2581396efe26 |
| Accession Number: | edsdoj.bf5d2f74ba34f8f8e2c2581396efe26 |
| Database: | Directory of Open Access Journals |
| ISSN: | 17597714 17597706 |
|---|---|
| DOI: | 10.1111/1759-7714.15401 |
| Published in: | Thoracic Cancer |
| Language: | English |